Skip to main content

Tendinopathy

2
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 3 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
2 programs
1
1
SecukinumabPhase 3Monoclonal Antibody1 trial
secukinumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03344640Completed96Est. Oct 2019
NCT05569174Completed62Est. Dec 2024
Biosplice Therapeutics
2 programs
SM04755PHASE_11 trial
SM04755PHASE_11 trial
Active Trials
NCT03502434Completed223Est. Nov 2017
NCT03229291Completed24Est. Jun 2017
Purdue Pharma
Purdue PharmaCT - Stamford
1 program
Amino AcidsN/A1 trial
Active Trials
NCT04067479Completed7Est. Dec 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozSecukinumab
Sandozsecukinumab
Biosplice TherapeuticsSM04755
Biosplice TherapeuticsSM04755
Purdue PharmaAmino Acids

Clinical Trials (5)

Total enrollment: 412 patients across 5 trials

NCT05569174SandozSecukinumab

Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy

Start: Dec 2022Est. completion: Dec 202462 patients
Phase 3Completed
NCT03344640Sandozsecukinumab

Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy

Start: Dec 2017Est. completion: Oct 201996 patients
Phase 2Completed
NCT03502434Biosplice TherapeuticsSM04755

A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers

Start: Sep 2017Est. completion: Nov 2017223 patients
Phase 1Completed
NCT03229291Biosplice TherapeuticsSM04755

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects

Start: Nov 2016Est. completion: Jun 201724 patients
Phase 1Completed
NCT04067479Purdue PharmaAmino Acids

Can Amino Acid Supplementation Augment the Anabolic Response in Tendon After Exercise

Start: May 2017Est. completion: Dec 20227 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.